Intraocular lens

BVI Launches PODEYE Hydrophobic Monofocal IOL in Japan

Retrieved on: 
星期四, 四月 18, 2024
Surgeon, GFY, Lens, POD, Intraocular lens, Health, PMDA, Ophthalmology, Pharmaceutical industry

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) --  BVI, the most dynamic, diversified company in ophthalmology, announced today the official launch of the PODEYE hydrophobic monofocal IOL in Japan following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The achievement represents another significant step in BVI’s plan to launch its range of IOLs in Japan over the near-term.

Key Points: 
  • BVI continues to execute its roadmap of IOL launches in Japan, the world's third-largest IOL-valued market1
    The PODEYE hydrophobic monofocal is perfectly suited to the Japanese market, where hydrophobic IOLs constitute almost 96% of the total monofocal IOL units in Japan1
    Following the 2023 launch of FINEVISION HP Hydrophobic Trifocal IOL, PODEYE becomes the second BVI IOL to be available in Japan
    WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) --  BVI, the most dynamic, diversified company in ophthalmology, announced today the official launch of the PODEYE hydrophobic monofocal IOL in Japan following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • Anticipate more groundbreaking product launches from us in Japan and many other major markets globally.” said Shervin Korangy, President and CEO of BVI.
  • Given that Japan is primarily a hydrophobic market, surgeons in Japan, like their counterparts worldwide, will appreciate the proprietary, hydrophobic ‘GFY®’ material from which BVI IOLS are made providing 100% glistening-free material.
  • Alongside its patented GFY material featured exclusively in BVI lenses, BVI also develops and supplies approximately 20% of IOL material for competing IOL companies globally from its facility in Florida, US.

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on: 
星期二, 四月 9, 2024
Device, Intraocular lens, IOL, CDRH, Health equity, Partnership, Patient, SAN, Research, American Academy, Manuscript, MD, ENT, Quality, Safety, FDA, Cataract, Food, Medicine, Dentistry

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points: 
  • Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
  • “The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
  • “We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
  • Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

EyeCare Partners Announces New Refractive Cataract Anterior Segment Fellowship and Launch of ECP Foundation

Retrieved on: 
星期四, 四月 4, 2024
Optical, Surgery, Health, Other Education, Philanthropy, Education, Foundation, Training, Disease burden, Partner, ECP, RCAS, Density, Intraocular lens, Growth, Convention, Refractive surgery, Physician, ASCRS, Telecanthus, Knowledge, Research, Meibomian gland dysfunction, Fellow, Trifocal lenses, Science, Patient satisfaction, Cataract, Mentorship, Quality of life, Surgeon, Society, Ophthalmology, Nursing

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.

Key Points: 
  • EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
  • The company is launching two new initiatives to elevate eye care – the Refractive Cataract Anterior Segment (RCAS) Fellowship and the ECP Foundation.
  • This one-year program provides residency graduates comprehensive training in the latest advancements in refractive cataract and anterior segment surgeries.
  • “We implement this mission through three programs: ECP GIVES, ECP EDUCATES and ECP CARES,” said Amy Jones, ECP Foundation President.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
星期三, 三月 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India

Retrieved on: 
星期二, 三月 12, 2024
Biotechnology, General Health, Optical, Health, Friends, Intraocular lens, DSM-IV codes, Presbyopia, Patient, Cataract, LOL, Surgeon, Haze, GLARE, Patient satisfaction, Ageing

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India.
  • At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” said Amar Vyas, Country Head of Alcon India.
  • “Clareon builds on Alcon’s long legacy of IOL innovation and is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems.
  • *,β,19,20 Clareon IOLs have been extensively researched, with inclusions in 30 published studies worldwide.

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
星期三, 三月 6, 2024
Biotechnology, Health, Optical, Love, Patient satisfaction, Intraocular lens, Eye, Patient, IOL, Medical device

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • Vivity is available in more than 80 countries, including Australia, Brazil, Canada, China, France, Germany, Japan, India, Italy, South Korea, Spain, U.K. and U.S. Alcon offers a family of leading IOLs designed to meet the unique vision needs of patients, including Vivity and PanOptix®—the most implanted PCIOLs worldwide—as well as Monofocal and Toric options.
  • PanOptix surpassed 1M implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.alcon.ca .

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

Retrieved on: 
星期三, 三月 6, 2024
Medical Devices, Health, Surgery, General Health, Optical, Biotechnology, Patient satisfaction, Presbyopia, Cataract, Intraocular lens, Registry, Eye, Telecanthus, Patient, Glaucoma

Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.

Key Points: 
  • Vivity is designed to simplify presbyopia correction, prioritizing patient satisfaction while minimizing surgeon and clinic chair time.
  • Recent, large-scale real-world data underscores the impact of Vivity on patients across the globe.
  • The Vivity Registry Study4+ includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy, as well as post-refractive eyes.
  • PanOptix surpassed one million implants in early 2022, and is the most implanted trifocal worldwide.5,6 For more information, please visit www.ClareonIOL.com .

New Swiss Made Features for Cataract Surgery Lens Selection

Retrieved on: 
星期四, 二月 22, 2024
Technology, Medical Devices, Surgery, Health Technology, Software, Other Health, Biometrics, Biotechnology, Health, Optical, Astigmatism, PCA, Biostatistics, Multimedia, Lens, Retina, Cataract, Intraocular lens, Vision, Image, Ophthalmology, Patient, Headache, Telescopic sight

The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.

Key Points: 
  • The company Swiss Advanced Vision (SAV-IOL SA) has announced the launch of New Features for its Toric Calculator improving the overall calculation experience.
  • View the full release here: https://www.businesswire.com/news/home/20240222791326/en/
    Launch of New Features, discover the unique Incision Location Optimization tool on SAV-IOL Toric Calculator.
  • Since 2009, the Swiss company has been developing advanced IOLs with the goal to restore the missing accommodation left by the removal of the natural lens.
  • Swiss Advanced Vision will keep the pace of innovative product development and is already working on new functionalities for their users, stay tuned!

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Retrieved on: 
星期三, 二月 21, 2024
Medical Supplies, Medical Devices, Health, Surgery, Pharmaceutical, Optical, Acquisition, Ophthalmology, Bausch, Care, Forecasting, News, Bausch & Lomb, Intraocular lens, Adjustment, GAAP, EPS, Ultra, Video game

For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.

Key Points: 
  • For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $0.24, as compared to $0.23 for the fourth quarter of 2022.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the full year of 2023 was $0.73, as compared to $1.07 for the full year of 2022.
  • Bausch + Lomb provided guidance for the full year of 2024, as follows.

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

Retrieved on: 
星期一, 二月 5, 2024
Well, Partnership, Ophthalmology, Growth, Gulf Cooperation Council, Intraocular lens, JV, Country, Patient, Presbyopia, Kingdom, Joint venture, Charge density, Astigmatism

The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.

Key Points: 
  • The JV will have exclusive rights to SIFI's range of IOLs, including the innovative Extended Depth of Focus ("EDOF") IOLs.
  • The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step.
  • Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs.
  • "It is therefore a great honor to invest alongside SIFI and bring such innovation to ophthalmologists and patients".